PSA bounce: understanding temporal fluctuations in prostate cancer after external radiotherapy.

Purpose: Prostate-specific antigen (PSA) bounce is a transient elevation in PSA levels commonly observed after radiotherapy. This study aims to investigate the characteristics, timing, and clinical implications of PSA bounce (PSA-B) in prostate cancer patients treated with external beam radiotherapy (EBRT), exploring potential causes and its relevance in patient management.

Materials And Methods: Between 2013 and 2019, 629 patients with localized prostate cancer were treated with EBRT.

DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response.

The integrated stress response (ISR) is a conserved pathway in eukaryotic cells that is activated in response to multiple sources of cellular stress. Although acute activation of this pathway restores cellular homeostasis, intense or prolonged ISR activation perturbs cell function and may contribute to neurodegeneration. DNL343 is an investigational CNS-penetrant small-molecule ISR inhibitor designed to activate the eukaryotic initiation factor 2B (eIF2B) and suppress aberrant ISR activation.

When you think you should transfuse…don't!

A 48-year-old female presented to the emergency department with severe fatigue. Admission laboratory test results were hemoglobin 6.6 g/dL, platelet count 287,000/μL, and white blood cell count 25,200/μL.

Family Intervention in Severe Mental Disorder: An Online Intervention Format in Psychosocial Rehabilitation Centers.

Unlabelled: The use of new technologies and online interventions with family members of people affected by severe mental disorders (SMD) seems to emerge as a promising complementary strategy to face-to-face care. The article presents a new online intervention format, aimed at relatives of people with SMD. A qualitative methodology sequenced in seven phases has been used.

Comparison of RhD Typing Results by Serology and Molecular Methods.

Objective: Molecular testing determines D antigen status when abnormal serologic results are observed. Molecular testing is routinely batched, resulting in longer turnaround time for abnormal D status resolution. During the interim, obstetric patients with questionable/uninterpretable and weak D typing results by serology, per the immunohematology reference laboratory (IRL) policy, will receive RhD negative blood.